Researchers Behind First Sickle Cell CRISPR Therapy Win $3 Million Prize

Drs. Swee Lay Thein and Stuart Orkin honored for work leading to groundbreaking gene-editing treatment.

Apr. 19, 2026 at 12:00am

Got story updates? Submit your updates here. ›

An extreme close-up X-ray image revealing the ghostly, glowing internal structure of a sickle-shaped red blood cell, conceptually illustrating the genetic basis of sickle cell disease.The groundbreaking gene therapy that earned a $3 million prize aims to correct the genetic defect that causes sickle-shaped red blood cells, a hallmark of the deadly blood disorder.Los Angeles Today

The 2026 Breakthrough Prize in Life Sciences was awarded to Dr. Swee Lay Thein of the National Heart, Lung and Blood Institute and Dr. Stuart H. Orkin of Harvard University for their research that enabled the development of Casgevy, the first approved gene therapy using CRISPR to treat the blood disorders sickle cell disease and beta-thalassemia.

Why it matters

Sickle cell disease affects millions globally, predominantly in Africa, and can cause excruciating pain, organ damage, and early death. Casgevy represents a major breakthrough as the first 'functional cure' for these deadly blood disorders, though the treatment process remains physically grueling and inaccessible in many parts of the world where the diseases are most prevalent.

The details

Thein's research in the 1980s uncovered how certain genetic variants allow some patients to continue producing 'fetal hemoglobin' into adulthood, mitigating sickle cell symptoms. Orkin's work then showed that the BCL11A gene acts as a 'repressor' that turns off fetal hemoglobin production, making it a viable target for gene editing. Vertex Pharmaceuticals then used CRISPR to disable BCL11A, leading to the development of Casgevy - a therapy that extracts a patient's bone marrow, edits the cells, and reinfuses them to produce red blood cells with high levels of fetal hemoglobin.

  • The 2026 Breakthrough Prize in Life Sciences was awarded on April 18, 2026.
  • Thein began her research on sickle cell disease and beta-thalassemia in the 1980s.

The players

Dr. Swee Lay Thein

A senior investigator at the National Heart, Lung and Blood Institute (NHLBI) who conducted pioneering research in the 1980s that uncovered the genetic basis for why some sickle cell and beta-thalassemia patients have milder forms of the diseases.

Dr. Stuart H. Orkin

A pediatric hematologist and oncologist at Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, and Howard Hughes Medical Institute who showed how the BCL11A gene acts as a repressor of fetal hemoglobin production, making it a viable target for gene editing.

Vertex Pharmaceuticals

The biotech company that used the CRISPR gene-editing tool to disable the BCL11A repressor gene, leading to the development of Casgevy - the first approved gene therapy to functionally cure sickle cell disease and severe beta-thalassemia.

Got photos? Submit your photos here. ›

What they’re saying

“I feel extremely honored, overwhelmed and humbled.”

— Dr. Swee Lay Thein

What’s next

Scientists are now working on 'in vivo' gene therapy approaches that would involve directly injecting the gene-editing machinery into patients, eliminating the need for the grueling process of extracting, editing, and reinfusing bone marrow cells. Researchers are also continuing to explore additional drug treatments, including a medication called Mitavipat that has shown promise in improving the overall health of red blood cells in sickle cell and beta-thalassemia patients.

The takeaway

The Breakthrough Prize-winning research that led to Casgevy represents a major milestone in the fight against sickle cell disease and beta-thalassemia, providing the first 'functional cure' for these devastating blood disorders. However, the high cost and physical toll of the current treatment process means more work is needed to develop safer, more accessible therapies that can reach the millions affected by these diseases worldwide.